D-type neuropeptide decorated AIEgen/RENP hybrid nanoprobes with light-driven ROS generation ability for NIR-II fluorescence imaging-guided through-skull photodynamic therapy of gliomas

Xuelu He; Yuan Luo; Yanying Li; Yuanbo Pan; Ryan T. K. Kwok; Lulu He; Xiaolin Duan; Pengfei Zhang; Aiguo Wu; Ben Zhong Tang; Juan Li

doi:10.1002/agt2.396

Aggregate ›› 2024, Vol. 5 ›› Issue (1) :396 DOI: 10.1002/agt2.396

RESEARCH ARTICLE

D-type neuropeptide decorated AIEgen/RENP hybrid nanoprobes with light-driven ROS generation ability for NIR-II fluorescence imaging-guided through-skull photodynamic therapy of gliomas

Author information +

¹. Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Sciences (CAS) Key Laboratory of Magnetic Materials and Devices, Ningbo Cixi Institute of Biomedical Engineering, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, P. R. China

². Guangdong Key Laboratory of Nanomedicine, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS-HK Joint Lab for Biomaterials, Research Laboratory for Biomedical Optics and Molecular Imaging, Shenzhen Key Laboratory for Molecular Imaging, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, P. R. China

³. Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction and Institute for Advanced Study, The Hong Kong University of Science and Technology (HKUST), Kowloon, P. R. China

⁴. School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, P. R. China

pf.zhang@siat.ac.cn

aiguo@nimte.ac.cn

tangbenz@cuhk.edu.cn

lij@nimte.ac.cn

Show less

History +

PDF

Abstract

Glioma is one of the most common malignant tumors of the central nervous system, leading high mortality rates in human. Aggregation-induced emission (AIE) photosensitizers-based photodynamic therapy (PDT) has emerged as a promising therapeutic strategy for least-invasive treatment of glioma, which involves local irradiation of the tumor using an external near-infrared (NIR) laser. Unfortunately, most AIE photosensitizers suffered from poorly penetration of the visible light excitation, bad spatiotemporal resolution in deep tissues and low efficient blood-brain barrier (BBB) crossing ability, which greatly limited the clinical practice of AIE photosensitizers for especially deep-seated brain tumor treatment. In this work, we developed a multifunctional NIR-driven theranostic agent through hybrid of AIE photosensitizers TIND with rare-earth doping nanoparticles (RENPs) NaGdF₄:Nd/Yb/Tm with up/down dual-mode conversion luminescence. The theranostic agent was further decorated with D-type neuropeptide ^DNPY for crossing BBB and targeting glioma. Under the 808-nm light irradiation, the down-conversion NIR-II luminescence could indicate the position glioma and the upconversion NIR-I luminescence could trigger the AIE photosensitizers producing reactive oxygen species to inhibit orthotopic glioma tumor growth in situ. These results demonstrate that the integration of Dtype neuropeptide, AIE photosensitizers and RENPs could be promising candidates for in vivo NIR-II fluorescence image-guided through-skull PDT treatments of brain tumors.

Keywords

aggregation-induced emission / D-type neuropeptide / glioma / photodynamic therapy / rare-earth doping nanoparticles

Cite this article

Download citation ▾

Xuelu He, Yuan Luo, Yanying Li, Yuanbo Pan, Ryan T. K. Kwok, Lulu He, Xiaolin Duan, Pengfei Zhang, Aiguo Wu, Ben Zhong Tang, Juan Li. D-type neuropeptide decorated AIEgen/RENP hybrid nanoprobes with light-driven ROS generation ability for NIR-II fluorescence imaging-guided through-skull photodynamic therapy of gliomas. Aggregate, 2024, 5(1): 396 DOI:10.1002/agt2.396

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	J. T. Huse, E. C. Holland, Nat. Rev. Cancer 2010, 10, 319.

[2]	D. N. Louis, A. Perry, P. Wesseling, D. J. Brat, I. A. Cree, D. Figarella-Branger, C. Hawkins, H. K. Ng, S. M. Pfister, G. Reifenberger, R. Soffietti, A. von Deimling, D. W. Ellison, Neuro-Oncology 2021, 23, 1231.

[3]	R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, CA Cancer J. Clin. 2022, 72, 7.

[4]	N. Sanai, M. S. Berger, Neurosurgery 2008, 62, 753.

[5]	H. S. Friedman, T. Kerby, H. Calvert, Clin. Cancer Res. 2000, 6, 2585.

[6]	A. Omuro, L. M. DeAngelis, JAMA 2013, 310, 1842.

[7]	N. A. O Bush, S. M. Chang, M. S. Berger, Neurosurg. Rev. 2017, 40, 1.

[8]	K. J. Langen, N. Galldiks, E. Hattingen, N. J. Shah, Nat. Rev. Neurosci. 2017, 13, 279.

[9]	X. Li, J. F. Lovell, J. Yoon, X. Chen, Nat. Rev. Clin. Oncol. 2020, 17, 657.

[10]	J. Chen, T. Fan, Z. Xie, Q. Zeng, P. Xue, T. Zheng, Y. Chen, X. Luo, H. Zhang, Biomaterials 2020, 237, 119827.

[11]	W. Fan, P. Huang, X. Chen, Chem. Soc. Rev. 2016, 45, 6488.

[12]	J. Ni, Y. Wang, H. Zhang, J. Z. Sun, B. Z. Tang, Molecules 2021, 26, 268.

[13]	S. Wang, X. Wang, L. Yu, M. Sun, Photodiagnosis Photodyn. Ther. 2021, 34, 102254.

[14]	S. D. Xu, Y. Y. Yuan, X. L. Cai, C. J. Zhang, F. Hu, J. Liang, G. X. Zhang, D. Q. Zhang, B. Liu, Chem. Sci. 2015, 6, 5824.

[15]	X. Z. Zhao, J. P. Liu, J. L. Fan, H. Chao, X. J. Peng, Chem. Soc. Rev. 2021, 50, 4185.

[16]	K. Wanderi, Z. Cui, Exploration 2022, 2, 20210097.

[17]	J. Lv, Y. Xing, X. Li, X. Du, Exploration 2022, 2, 20210162.

[18]	D. Mao, F. Hu, Z. G. Yi, K. Kenry, S. D. Xu, S. Q. Yan, Z. C. Luo, W. B. Wu, Z. H. Wang, D. L. Kong, X. G. Liu, B. Liu, Sci. Adv. 2020, 6, eabb2712.

[19]	Y. Guan, H. G. Lu, W. Li, Y. D. Zheng, Z. Jiang, J. L. Zou, H. Gao, ACS Appl. Mater. Interfaces 2017, 9, 26731.

[20]	Q. Xin, H. Ma, H. Wang, X. Zhang, Exploration 2023, 3, 20210473.

[21]	F. Li, Y. Du, J. Liu, H. Sun, J. Wang, R. Li, D. Kim, T. Hyeon, D. Ling, Adv. Mater. 2018, 30, 1802808.

[22]	G. Jin, R. He, Q. Liu, M. Lin, Y. Dong, K. Li, B. Z. Tang, B. Liu, F. Xu, Theranostics 2019, 9, 246.

[23]	P. L. Kubben, K. J. ter Meulen, O. Schijns, M. P. ter Laak-Poort, J. J. van Overbeeke, H. van Santbrink, Lancet Oncol. 2011, 12, 1062.

[24]	W. Chen, J. Nucl. Med. 2007, 48, 1468.

[25]	P. Beard, Interface Focus 2011, 1, 602.

[26]	L. Z. Zhao, J. Y. Zhu, Y. J. Cheng, Z. J. Xiong, Y. Q. Tang, L. L. Guo, X. Y. Shi, J. H. Zhao, ACS Appl. Mater. Interfaces 2015, 7, 19798.

[27]	Y. Wu, F. Zhang, View 2020, 1, 20200068.

[28]	Z. Hu, C. Fang, B. Li, Z. Zhang, C. Cao, M. Cai, S. Su, X. Sun, X. Shi, C. Li, T. Zhou, Y. Zhang, C. Chi, P. He, X. Xia, Y. Chen, S. S. Gambhir, Z. Cheng, J. Tian, Nat. Biomed. Eng. 2020, 4, 259.

[29]	F. Wang, H. Wan, Z. Ma, Y. Zhong, Q. Sun, Y. Tian, L. Qu, H. Du, M. Zhang, L. Li, H. Ma, J. Luo, Y. Liang, W. J. Li, G. Hong, L. Liu, H. Dai, Nat. Methods 2019, 16, 545.

[30]	S. Zhu, R. Tian, A. L. Antaris, X. Chen, H. Dai, Adv. Mater. 2019, 31, 1900321.

[31]	Y. Zhong, Z. Ma, S. Zhu, J. Yue, M. Zhang, A. L. Antaris, J. Yuan, R. Cui, H. Wan, Y. Zhou, W. Wang, N. F. Huang, J. Luo, Z. Hu, H. Dai, Nat. Commun. 2017, 8, 737.

[32]	Y. Zhong, Z. Ma, F. Wang, X. Wang, Y. Yang, Y. Liu, X. Zhao, J. Li, H. Du, M. Zhang, Q. Cui, S. Zhu, Q. Sun, H. Wan, Y. Tian, Q. Liu, W. Wang, K. C. Garcia, H. Dai, Nat. Biotech. 2019, 37, 1322.

[33]	H. Li, X. Wang, X. Li, S. Zeng, G. Chen, Chem. Mater. 2020, 32, 3365.

[34]	L. Youbin, M. Jiang, Z. Xue, S. Zeng, Theranostics 2020, 10, 6875.

[35]	R. Daneman, Ann. Neurol. 2012, 72, 648.

[36]	Y. Chen, L. Liu, Adv. Drug Delivery Rev. 2012, 64, 640.

[37]	X. Wei, C. Zhan, Q. Shen, W. Fu, C. Xie, J. Gao, C. Peng, P. Zheng, W. Lu, Angew. Chem. Int. Ed. 2015, 54, 3023.

[38]	Y. Li, Y. Pan, Y. Wang, Z. Jiang, O. U. Akakuru, M. Li, X. Zhang, B. Yuan, J. Xing, L. Luo, D. Larhammar, A. Wu, J. Li, Nano Today 2022, 44, 101465.